**This event has now run**

Day one of our main agenda will explore if there are better ways of identifying neoantigens and will consider how clinical trial progression varies for the different delivery methods. See all topics and their summaries in the full event guide for more details.

7:20 am Registration & Breakfast

8:20 am Chair’s Opening Remarks

Engineering Personalised Vaccines by Optimising Neoantigen Cell Therapy

8:30 am A Landscape Analysis Of Neoantigens Used In Cancer Vaccines


• An overview of the current preclinical and clinical view of Cancer Vaccines which utilise a
• Neoantigen selection technologies and current trends
• Future directions of the neoantigen space

9:00 am Considerations for the Development of Personalised Neoantigen-Based Cancer Vaccines


• Reviewing updates on current individualised cancer vaccine clinical approaches, successes, and challenges
• Considering factors for process design and specifications for a personalised neoantigen-based vaccine and a customised neoantigen based cell therapy
• Exploring approaches for dealing with human and process variability

9:30 am Don’t miss what’s (ImmunoID) NeXT: A Comprehensive Platform for Immuno-Oncology – Improving Neoantigen Prediction, Evaluating Tumor Dynamics & Immunogenomics Profiling

  • Maik Pruess Senior Field Applications Scientist, Personalis


• Accurate assessment of mutational landscape and putative neoantigens from the analytically-validated exome and transcriptome ImmunoID NeXT platform
• Improved neoantigen presentation and binding predictions through a machine learning algorithm, SHERPA, built upon high quality immunopeptidomics training data from mono-allelic, and multi-allelic samples
• Comprehensive immunogenomics profiling from a single sample to guide neoantigen-based therapies today and enable future biomarker discovery

10:00 am Uncovering the Benefits of Personalised Vaccines in a Clinical Setting


• Uncovering features of peptide anti-cancer vaccines that makes this class attractive
• Proving benefits of peptide cancer vaccines in the clinic- which setting?
• Discussing considerations of dose and schedule

10:30 am Rational Pipelines for the Identification of Tumour Specific Neoantigens


• Rational approach to neoantigen identification
• Building tailor-made architecture, infrastructure and pipelines for neoantigen identification
• Integrating across various data types to extract biological signal

10:40 am Industry Leader’s Fireside Chat


• Highlighting the greatest challenges in cancer vaccine development and where the opportunity lies
• Considering the competitive vaccine manufacturing landscape and how the neoantigen community will compete
• Meeting investor expectations for timelines and budgets while performing true discovery science

11:00 am Morning Refreshments & Structured Networking


Increasing Precision Accuracy in Identifying Neoantigens

11:30 am Robust Neoantigen Predictions by Deep Deconvolution of Immunopeptidome


  • Understanding how to identify the most potent antigens
    to elicit an immune response
  • Leveraging the precision and accuracy of throughput assays and how this improves neoantigen selection
  • Discussing the improvement in turnaround time

12:00 pm Current Identification of Neoantigens & How this Translates to Preclinical Settings


  • Considering the current overview of identification and prioritisation of cancer neoantigens
  • Highlighting the limitations of current neoantigen prediction pipelines
  • Discussing broader challenges associated with cancer neoantigen vaccines

12:30 pm Identification of Actionable CD8 Antigens & TCRs Recognising them – a Systematic Platform Approach


  • Uncovering a high-precision platform using analytical engineered cells to recapitulate antigen presentation and TCR response
  • Utilising the comprehensive identification of HLA-restricted epitopes within analytical open reading frames
  • Utilising the comprehensive identification of HLA-restricted epitopes within analytical open reading frames


Optimising Vaccine Manufacturing for Targeting Neoantigens

11:30 am Insights to Assist Finding the Right Vaccine Platforms


  • Developing individualised therapeutic cancer vaccines against neoantigens arising from somatic gene mutations in malignant cells
  • Demonstrating induction of strong cancer-specific immune responses which lead to clinical responses in several patients

12:00 pm Improving Neoantigen DNA Vaccines for Optimal Anti-Tumor T Cell Immunity


• Discussing the importance of MHC class II restricted neoantigens
• PyroVant: a novel pyroptotic adjuvant
• AmpliVax: a method to produce synthetic DNA vaccines
• Optimisation of intradermal vaccine delivery

12:30 pm Oral Administration of DNA-Based Vaccines to Stimulate a Strong Immune Response Towards Mutated Cancer Antigen(s)

  • Heinz Lubenau Chief Executive Officer & Co-Founder, Vaximm GmbH


  • Analysing the benefits of oral administration of DNA as opposed to injection
  • Identifying the success of stimulating an immune response
  • Presenting unequivocal clinical data proving the success of the method



1:00 pm Lunch & Networking

Methods & Innovative Tools for Neoantigen Prediction

2:00 pm Identification of Frame Neoantigens to Develop Highly Immunogenic Cancer Vaccines


  • Identifying Frame neoantigens derived from neo-open reading frames in human cancers identification of all neoantigens resulting from SVs and subsequent RNA splicing
  • Utilising a unique combination of tumour sequencing technologies for comprehensive detection of neoantigens at high sensitivity
  • Demonstrating pre-clinical proof of the overwhelming immunogenicity of Frame neoantigens

2:30 pm Design of Neoantigen-Based Cancer Vaccines for Potent & Effective Anti-Tumour T Cell Immunity


  • Discussing the unique proprietary databases and setup to interrogate cancers throughout their huge diversities
  • Considering the development of tools that can help in elucidating the mechanisms underlying the response to the vaccination

Advancing Clinical Trial Design & Unifying Data

2:00 pm Clinical Trial Design Showing Vaccine-Induced Clinical Efficacy


  • Discussing the current methods of testing immunogenicity
  • Expanding the focus to testing clinical outcomes
  • Demonstrating clinical benefits of neoantigens by controlled group clinical trial




2:30 pm Phase I Clinical Trial Success of Individualised Immunotherapies


  • Developing individualised immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies
  • Exploiting the mechanisms of the immune response to enable patients to defend themselves against cancer

3:00 pm Afternoon Refreshments & Structured Networking

Insights to Assist Finding the Right Vaccine Platforms

3:30 pm Using Immunopeptidomics to Identify Auto-antigens: Neutrophil Extracellular Traps

  • Julie Rumble Manager of Immunology Contract Services, Cayman Chemical


• Neutrophil extracellular traps (NETs) are a powerful tool that neutrophils use to capture and eliminate pathogens but are also associated with autoimmune conditions like lupus and rheumatoid arthritis.
• Post-translational modifications of self-proteins associated with NETs could stimulate non-self immune responses to drive autoimmune activation.
• Identification of NET-associated antigens presented by antigen-presenting cells may help to better understand the etiology of these diseases.

4:00 pm PeptiCRAd – Flexible Peptide Delivery Platform for Therapeutic Cancer (Neoantigen) Vaccines

  • Sari Pesonen Co-Founder & Chief Scientific Officer, Valo Therapeutics


• Reviewing how the safety and efficacy of these vaccine modalities remains unclear in certain cancer patients

• Addressing the complex manufacturing process and regulatory aspects

• Developing neoantigen vaccines based on peptides and viral adjuvants

4:30 pm Optimising DNA-Based Cancer Vaccines for Improved Immunogenicity

  • Jessica Matta Co-Founder & Chief Executive Officer & Chief Scientific Officer, Odimma therapeutics


• Developing neoantigen cancer vaccines based on DNA done at a very small scale
• Addressing the reduced manufacturing time as the production process (there are a lot of benefits in quickly producing a vaccine per patient)
• Utilising the benefits of adjuvants with DNA to induce strong cancer-specific immune responses
• Currently in preclinical development and planning to move into phase 1 next year

5:00 pm Comfort Break

5:15 pm Overcoming RNA-Based Vaccine Challenges for Effective Cancer Vaccine Therapy

  • Heinrich Haas Vice President Formulation and Drug Development, BioNTech AG


• Clarifying the success of the RNA-based platform due to the COVID-19 vaccine is easily translatable to cancer vaccine
• Improving vaccine activity by combining with RNA encoded cytokines

5:45 pm Is There a Single “Best” Platform or Will it be “Fit to Purpose”?

  • Jeffrey Bockman Executive Vice President of Commercial BioConsulting & Head of Oncology, Lumanity


• Analysing the advantages, disadvantages and comparisons of the DNA, Peptide, RNA, and Virus-based and other novel vaccine platforms
• Harmonisation of clinical outcomes and immune correlates
• Considering if we can we get better at predictive animal models?
• Questioning what other signals we need to provide to the immune system, either built into the vaccine or given concomitantly (checkpoints, costims, cytokines, innate immunity boosters, etc.)

6:15 pm Chair’s Closing Remarks

6:20 pm Scientific Poster Session


After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda allowing you to connect with your peers in a relaxed atmosphere and continue to develop new and existing relationships. During this session, scientific posters will be presented on the cutting-edge advances of neoantigen therapeutics.